Evidence map›Paper›PMID 26483062›Full record

SynthesisJournal of the National Comprehensive Cancer Network : JNCCN2015

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.

Stuart A Grossman, Susannah Ellsworth, Jian Campian, Aaron T Wild, Joseph M Herman, Dan Laheru, Malcolm Brock, Ani Balmanoukian, Xiaobu Ye

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the National Comprehensive Cancer Network : JNCCN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 187 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 2 syntheses or guidelines pooled it, 315 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Stuart A GrossmanFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Susannah EllsworthFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Jian CampianFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Aaron T WildFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Joseph M HermanFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Dan LaheruFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Malcolm BrockFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Ani BalmanoukianFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Xiaobu YeFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Washington University, St. Louis, Missouri; Memorial Sloan Kettering Cancer Center, New York, New York; and The Angeles Clinic and Research Institute, Los Angeles, California.
Johns Hopkins University · USAngeles Clinic and Research Institute · USMemorial Sloan Kettering Cancer Center · USWashington University in St. Louis · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
NCI NIH HHS P30 CA006973NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

backgroundThe immune system plays an important role in cancer surveillance and therapy. Chemoradiation can cause severe treatment-related lymphopenia (TRL) (<500 cells/mm3) that is associated with reduced survival. MATERIALS AND

methodsData from 4 independent solid tumor studies on serial lymphocyte counts, prognostic factors, treatment, and survival were collected and analyzed. The data set included 297 patients with newly diagnosed malignant glioma (N=96), resected pancreatic cancer (N=53), unresectable pancreatic cancer (N=101), and non-small cell lung cancer (N=47).

resultsPretreatment lymphocyte counts were normal in 83% of the patient population, and no patient had severe baseline lymphopenia. Two months after initiating chemoradiation, 43% developed severe and persistent lymphopenia (P=.001). An increased risk for death was attributable to TRL in each cancer cohort (gliomas: hazard rate [HR], 1.8; 95% CI, 1.13-2.87; resected pancreas: HR, 2.2; 95% CI, 1.17-4.12; unresected pancreas: HR, 2.9; 95% CI, 1.53-5.42; and lung: HR, 1.7; 95% CI, 0.8-3.61) and in the entire study population regardless of pathologic findings (HR, 2.1; 95% CI, 1.54-2.78; P<.0001). Severe TRL was observed in more than 40% of patients 2 months after initiating chemoradiation, regardless of histology or chemotherapy regimen, and was independently associated with shorter survival from tumor progression.

conclusionsIncreased attention and research should be focused on the cause, prevention, and reversal of this unintended consequence of cancer treatment that seems to be related to survival in patients with solid tumors.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemoradiotherapyDisease-Free SurvivalFemaleGliomaHumansLymphocyte CountLymphopeniaMaleMiddle AgedPancreatic Neoplasms

Identifiers

PMID26483062
PMCPMC4778429
OpenAlexW1757492577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.